Abstract:IMPORTANCE: The dream enactment of rapid eye movement sleep behavior disorder (RBD) is often the first indication of an impending α-synuclein disorder, such as Parkinson disease, multiple-system atrophy, or dementia with Lewy bodies.OBJECTIVE: To provide an overview of RBD from the onset of dream enactment through the emergence of a parkinsonian disorder.EVIDENCE REVIEW: Peer-reviewed articles, including case reports, case series, retrospective reviews, prospective randomized trials, and basic science investigations, were identified in a PubMed search of articles on RBD from January 1, 1986, through July 31, 2014.FINDINGS: Under normal conditions, vivid dream mentation combined with skeletal muscle paralysis characterizes rapid eye movement sleep. In RBD, α-synuclein abnormalities in the brainstem disinhibit rapid eye movement sleep motor activity, leading to dream enactment. The behaviors of RBD are often theatrical, with complexity, aggression, and violence; fighting and fleeing actions can be injurious to patients as well as bed partners. Rapid eye movement sleep behavior disorder is distinguished from other parasomnias by clinical features and the demonstration of rapid eye movement sleep without atonia on polysomnography. Consistent with early neurodegeneration, patients with RBD demonstrate subtle motor, cognitive, and autonomic impairments. Approximately 50% of patients with spontaneous RBD will convert to a parkinsonian disorder within a decade. Ultimately, nearly all (81%-90%) patients with RBD develop a neurodegenerative disorder. Among patients with Parkinson disease, RBD predicts a non-tremor-predominant subtype, gait freezing, and an aggressive clinical course. The most commonly cited RBD treatments include low-dose clonazepam or high-dose melatonin taken orally at bedtime.CONCLUSIONS AND RELEVANCE: Treatment of RBD can prevent injury to patients and bed partners. Because RBD is a prodromal syndrome of Parkinson disease (or related disorder), it represents a unique opportunity for developing and testing disease-modifying therapies.

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update

Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease

RBD and Neurodegenerative Diseases.

Functional Neuroimaging in Idiopathic Rapid Eye Movement Sleep Behavior Disorder

Rapid Eye Movement Sleep Behavior Disorder in Patients with Probable Alzheimer’s Disease

Rapid Eye Movement Sleep Behavior Disorder As a Predicting Phenomenon of Α-Synucleinopathies( Report of 1 Case)

Morbidities in rapid eye movement sleep behavior disorder

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

Secondary RBD: Not just neurodegeneration

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

Review of rapid eye movement behavior sleep disorders

Clinical Biomarkers of Neurodegeneration in REM Sleep Behavior Disorder

Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions

Retinal Nerve Fiber Layer Thinning: a Window into Rapid Eye Movement Sleep Behavior Disorders in Parkinson’s Disease

Does idiopathic REM sleep behavior disorder (iRBD) really exist? What are the potential markers of neurodegeneration in iRBD?

REM Sleep Behaviour Disorder: Prodromal and Mechanistic Insights for Parkinson's Disease

Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease

REM sleep behavior disorder and neuropathology in Parkinson's disease

REM Behavior Disorder: Implications for PD Therapeutics

From Rapid Eye Movement Sleep Behavior Disorder to Parkinson’s Disease: Possible Predictive Markers of Conversion